December 17, 2020 03:20 AM ESTUpdated 01:32 PM
Deals

Build­ing its neu­ro pipeline, No­var­tis antes up $210M cash to buy a biotech part­ner drug­ging 'both fla­vors' of NM­DA

Amber Tong

Af­ter J&J and Al­ler­gan shone a bright spot­light on the role of NM­DA re­cep­tors in psy­chi­atric dis­eases, No­var­tis has jumped in with both feet by …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Ca­griSe­ma’s weight loss da­ta dis­ap­point­ed. What does No­vo do next?

CMS ex­plains what went in­to its first round of drug price ne­go­ti­a­tions

FDA ap­proves Lil­ly's Zep­bound for sleep ap­nea, like­ly crack­ing open Medicare mar­ket

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Deer­field wins fight to ac­quire Sin­gu­lar Ge­nomics, beat­ing out Tang Cap­i­tal’s Con­cen­tra

A service from the Financial Times